ClinicalTrials.gg
CompletedNCT03745638Updated Sep 28, 2023Results posted

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 79 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
Largest of 15
631 · median 77
Started
2018
with 1 other
Phase 3
6 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one has the largest enrollment, is one of 2 that started in 2018, is one of 6 in phase 3, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic Dermatitis
  • Pruritus
  • Eczema
  • Topical Therapy
  • JAK Inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged ≥12 to 17 years, inclusive, and men and women aged ≥18 years.
  • Participants diagnosed with Atopic Dermatitis (AD) as defined by the Hanifin and Rajka criteria.
  • AD duration of at least 2 years.
  • Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at screening and Baseline [Vehicle Controlled (VC) Period] and 0 to 4 at Week 8 [Long-Term Safety (LTS) Period].
  • Participants with percentage of Body Surface Area (% BSA) (excluding scalp) of AD involvement of 3% to 20% at screening and Baseline (VC Period) and 0% to 20% at Week 8 (LTS Period).
  • Participants who agree to discontinue all agents used to treat AD from screening through the final follow-up visit.
  • Participants who have at least 1 "target lesion" that measures approximately 10 cm\^2 or more at screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the hands, feet, or genitalia.
  • Willingness to avoid pregnancy or fathering of children.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Baseline.
  • Concurrent conditions and history of other diseases:

    • .
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline.
    • Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline.
    • Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
    • Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.
    • Other types of eczema.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of any of the following treatments within the indicated before Baseline:

    • 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg. dupilumab).
    • 4 weeks - systemic or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg. mycophenolate or tacrolimus).
    • 2 weeks - immunizations and sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted).
    • 1 week - use of other topical treatments for AD (other than bland emollients). Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.
  • Participants who have previously received Janus kinase (JAK) inhibitors, systemic or topical.
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 2 weeks prior to Baseline and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's AD.
  • Positive serology test results at screening for (HIV) antibody.
  • Liver function tests: (AST) or alanine aminotransferase (ALT) ≥ 2 × (ULN); alkaline phosphatase and/or > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%).
  • Pregnant or lactating participants, or those considering pregnancy.
  • History of alcoholism or drug addiction within 1 year before screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration schedule and study assessments.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before Baseline with another medication or current enrollment in another investigational drug protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
631 participants (actual)

Study arms

  • Placebo comparator
    VC Period: Vehicle Cream BID

    Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Vehicle Cream

  • Experimental
    VC Period: Ruxolitinib 0.75% Cream BID

    Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib Cream

  • Experimental
    VC Period: Ruxolitinib 1.5% Cream BID

    Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib Cream

  • Experimental
    LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID

    Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the Long-term Safety (LTS) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib Cream

  • Experimental
    LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID

    Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib Cream

  • Experimental
    LTS Period: Ruxolitinib 0.75% Cream

    Arm description: Participants who applied ruxolitinib 0.75% cream during VC Period, continued applying ruxolitinib 0.75% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib Cream

  • Experimental
    LTS Period: Ruxolitinib 1.5% Cream

    Arm description: Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

    Also known as: INCB018424 Phosphate Cream

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75)

    EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

    Time frame: Baseline to Week 8

  2. VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score

    The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD in the daily diary by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours.

    Time frame: Baseline to Week 8

  3. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Each item asks the participant to rate the severity of the participant's sleep disturbance.

    Time frame: Baseline to Week 8

  4. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall)

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.

    Time frame: Baseline to Week 8

  5. VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: From first dose up to Week 8

  6. LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)

  7. VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4

    The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

    Time frame: Baseline to Weeks 2 and 4

  8. VC Period: Percentage of Participants Achieving IGA Scores of 0 or 1

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).

    Time frame: Weeks 2, 4 and 8

  9. LTS Period: Percentage of Participants Achieving IGA Scores of 0 or 1

    The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).

    Time frame: Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  10. VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4

    The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

    Time frame: Baseline to Weeks 2 and 4

  11. VC Period: Percentage of Participants Achieving EASI50

    EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.

    Time frame: Weeks 2, 4 and 8

  12. VC Period: Percentage of Participants Achieving EASI75

    EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

    Time frame: Weeks 2 and 4

  13. VC Period: Percentage of Participants Achieving EASI90

    EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.

    Time frame: Weeks 2, 4 and 8

  14. VC Period: Percent Change From Baseline in EASI Score

    EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  15. VC Period: Percent Change From Baseline In SCORing Atopic Dermatitis (SCORAD) Score

    The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  16. VC Period: Change From Baseline in Itch NRS Score

    The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  17. VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points

    The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.

    Time frame: Up to Week 8

  18. VC Period: Change From Baseline in Skin Pain NRS Score

    The Skin Pain NRS is a daily patient-reported measure (24-hour recall), using a diary, of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain). Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  19. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

    Time frame: Weeks 2 and 4

  20. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.

    Time frame: Weeks 2 and 4

  21. VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  22. VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  23. LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, and 52

  24. LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, and 52

  25. VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)

    Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  26. LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA

    Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  27. VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score

    The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (clear or almost clear) to 28 (very severe eczema). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  28. LTS Period: Change From Baseline in POEM Score

    The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, and 52

  29. VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 2, 4, and 8

  30. LTS Period: Change From Baseline in DLQI Score

    The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 12, 24, and 52

  31. VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score

    CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 2, 4, and 8

  32. LTS Period: Change From Baseline in CDLQI Score

    CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 12, 24, and 52

  33. VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4, and 8

  34. VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4, and 8

  35. VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4, and 8

  36. VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score

    EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  37. VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)

    The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  38. LTS Period: Change From Baseline in WPAI-SHP v2.0

    The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, 36, and 52

  39. VC Period: Trough Plasma Concentrations of Ruxolitinib

    Plasma samples were collected just before the morning application of study drug during each specified time point.

    Time frame: Pre-dose at Weeks 2, 4 and 8

  40. LTS Period: Trough Plasma Concentrations of Ruxolitinib

    Plasma samples were collected just before the morning application of study drug during each specified time point.

    Time frame: Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

07

Results

Posted Dec 17, 2021

Participant flow

A total of 631 participants took part in the study at 78 sites, 48 in North America and 30 in Europe from December 20, 2018 to December 01, 2020.

Vehicle Control Period (Day 1 to Week 8)
Participant flow — Vehicle Control Period (Day 1 to Week 8)
MilestoneVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Started1262522530000
Completed952222250000
Not completed3130280000
Withdrew: Adverse event4210000
Withdrew: Lack of efficacy1000000
Withdrew: Lost to follow-up51280000
Withdrew: Physician decision1100000
Withdrew: Pregnancy1000000
Withdrew: Protocol violation0300000
Withdrew: Withdrawal by subject1711190000
Withdrew: Reason not specified2100000
Long-Term Safety Period (Weeks 8 to 52)
Participant flow — Long-Term Safety Period (Weeks 8 to 52)
MilestoneVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Started0004847222225
Completed0003738176174
Not completed0001194651
Withdrew: Adverse event0000061
Withdrew: Lack of efficacy0001022
Withdrew: Lost to follow-up000351324
Withdrew: Physician decision0000130
Withdrew: Protocol violation0000010
Withdrew: Withdrawal by subject000731721
Withdrew: Reason not specified0000043

Outcome measures

PrimaryPercentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 815.1 (9.3 to 22.5)50.0 (43.7 to 56.3)53.8 (47.4 to 60.0)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 6.38 · 95% CI 3.556 to 11.923
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 7.50 · 95% CI 4.178 to 14.040
SecondaryVC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75)

EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75)
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75)24.6 (17.4 to 33.1)56.0 (49.6 to 62.2)62.1 (55.8 to 68.1)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 4.04 · 95% CI 2.441 to 6.808
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 5.22 · 95% CI 3.145 to 8.831
SecondaryVC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score

The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD in the daily diary by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score15.440.452.2
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = 0.0002 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 3.66 · 95% CI 1.773 to 8.083
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 6.01 · 95% CI 2.931 to 13.220
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Each item asks the participant to rate the severity of the participant's sleep disturbance.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score9.521.022.3
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = 0.0081 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 2.56 · 95% CI 1.242 to 5.723
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = 0.0039 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 2.74 · 95% CI 1.334 to 6.083
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall)

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall)
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall)13.220.221.6
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = 0.1421 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.67 · 95% CI 0.862 to 3.391
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = 0.0746 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.82 · 95% CI 0.949 to 3.665
SecondaryVC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

Time frame:
From first dose up to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
TEAE34.929.029.2
Treatment Emergent SAE1.60.40.8
SecondaryLTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

Time frame:
From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)
Reported as:
Number · percentage of participants
LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE
percentage of participantsLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
TEAE47.948.954.553.3
Treatment Emergent SAE6.32.12.31.3
SecondaryVC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4

The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 23.222.227.3
Week 46.342.546.6
SecondaryVC Period: Percentage of Participants Achieving IGA Scores of 0 or 1

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Achieving IGA Scores of 0 or 1
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 26.332.534.8
Week 415.153.254.9
Week 823.858.762.8
SecondaryLTS Period: Percentage of Participants Achieving IGA Scores of 0 or 1

The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).

Time frame:
Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
LTS Period: Percentage of Participants Achieving IGA Scores of 0 or 1
percentage of participantsLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Week 818.838.365.368.4
Week 1255.665.262.766.5
Week 1660.562.266.568.9
Week 2063.667.462.473.5
Week 2471.478.667.076.7
Week 2864.974.467.377.3
Week 3277.181.471.575.9
Week 3673.582.174.571.7
Week 4081.379.573.575.5
Week 4484.886.574.376.2
Week 4872.276.374.373.8
Week 5276.373.776.975.4
SecondaryVC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4

The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 25.126.333.5
Week 411.538.551.6
SecondaryVC Period: Percentage of Participants Achieving EASI50

EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Achieving EASI50
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 219.853.262.5
Week 427.868.775.5
Week 843.769.477.9
SecondaryVC Period: Percentage of Participants Achieving EASI75

EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Achieving EASI75
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 25.630.236.0
Week 414.351.658.5
SecondaryVC Period: Percentage of Participants Achieving EASI90

EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Achieving EASI90
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 22.412.719.8
Week 44.030.636.4
Week 89.538.144.3
SecondaryVC Period: Percent Change From Baseline in EASI Score

EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · percent change
VC Period: Percent Change From Baseline in EASI Score
percent changeVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Change From Baseline at Week 2-16.34 ± 3.42-51.82 ± 2.36-56.62 ± 2.35
Percent Change From Baseline at Week 4-23.03 ± 3.90-68.04 ± 2.66-71.08 ± 2.64
Percent Change From Baseline at Week 8-37.88 ± 3.72-71.01 ± 2.52-77.40 ± 2.49
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 · Least squares mean difference: -35.48 · 95% CI -43.64 to -27.32The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 · Least squares method of mean difference]: -40.29 · 95% CI -48.44 to -32.13The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 · Least squares mean difference: -45.01 · 95% CI -54.28 to -35.74The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 · Least squares mean difference: -48.05 · 95% CI -57.30 to -38.79The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 (The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.) · Least squares mean difference: -33.13 · 95% CI -41.95 to -24.30
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = < 0.0001 · Least squares mean difference: -39.52 · 95% CI -48.32 to -30.72The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Percent Change From Baseline In SCORing Atopic Dermatitis (SCORAD) Score

The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · percent change
VC Period: Percent Change From Baseline In SCORing Atopic Dermatitis (SCORAD) Score
percent changeVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Change From Baseline at Week 2-16.67 ± 34.152-43.96 ± 28.548-49.32 ± 31.878
Percent Change From Baseline at Week 4-27.68 ± 34.518-57.80 ± 28.635-61.33 ± 30.113
Percent Change From Baseline at Week 8-37.00 ± 36.392-62.14 ± 31.108-67.24 ± 28.711
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = < 0.0001 · Least squares mean difference: -25.3 · 95% CI -32.62 to -17.95P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = < 0.0001 · Least squares mean difference: -30.4 · 95% CI -37.68 to -23.06P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Change From Baseline in Itch NRS Score

The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in Itch NRS Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.89 ± 0.20-2.28 ± 0.14-2.53 ± 0.13
Change From Baseline at Week 4-1.08 ± 0.23-2.79 ± 0.16-3.16 ± 0.15
Change From Baseline at Week 8-1.54 ± 0.25-3.14 ± 0.17-3.53 ± 0.16
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.39 · 95% CI -1.87 to -0.91The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.64 · 95% CI -2.11 to -1.16The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.70 · 95% CI -2.25 to -1.15The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -2.08 · 95% CI -2.63 to -1.53The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.60 · 95% CI -2.20 to -1.01The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.99 · 95% CI -2.58 to -1.40The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points

The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.

Time frame:
Up to Week 8
Reported as:
Median · days
VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points
daysVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
≥ 2-Point Improvement in Itch NRS Score15.0 (10.0 to 22.0)4.0 (3.0 to 5.0)3.0 (3.0 to 4.0)
≥ 3-Point Improvement in Itch NRS Score27.0 (13.0 to 69.0)8.0 (7.0 to 11.0)6.0 (5.0 to 9.0)
≥ 4-Point Improvement in Itch NRS ScoreNA (28.0 to NA)14.0 (9.0 to 19.0)13.0 (9.0 to 15.0)
SecondaryVC Period: Change From Baseline in Skin Pain NRS Score

The Skin Pain NRS is a daily patient-reported measure (24-hour recall), using a diary, of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain). Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Skin Pain NRS Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.70 ± 1.746-1.90 ± 1.950-2.07 ± 2.164
Change From Baseline at Week 4-0.84 ± 2.307-2.36 ± 2.217-2.72 ± 2.513
Change From Baseline at Week 8-1.16 ± 2.610-2.55 ± 2.360-2.84 ± 2.743
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -1.2 · 95% CI -1.74 to -0.74P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -1.6 · 95% CI -2.11 to -1.13P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 25.213.714.7
Week 46.919.321.0
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 28.816.313.5
Week 413.220.619.2
SecondaryVC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.18 ± 0.45-1.72 ± 0.31-2.49 ± 0.30
Change From Baseline at Week 4-0.25 ± 0.50-2.58 ± 0.34-3.10 ± 0.33
Change From Baseline at Week 8-0.43 ± 0.59-2.97 ± 0.39-3.62 ± 0.39
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0049 · Least squares mean difference: -1.53 · 95% CI -2.60 to -0.47The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -2.31 · 95% CI -3.37 to -1.25The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0001 · Least squares mean difference: -2.33 · 95% CI -3.52 to -1.15The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -2.85 · 95% CI -4.03 to -1.67The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0004 · Least squares mean difference: -2.54 · 95% CI -3.93 to -1.14The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -3.18 · 95% CI -4.57 to -1.79The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.58 ± 0.49-1.76 ± 0.33-2.25 ± 0.33
Change From Baseline at Week 4-1.06 ± 0.55-2.71 ± 0.37-2.97 ± 0.36
Change From Baseline at Week 8-1.22 ± 0.62-3.34 ± 0.41-3.52 ± 0.40
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0487 · Least squares mean difference: -1.18 · 95% CI -2.35 to -0.01The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0049 · Least squares mean difference: -1.68 · 95% CI -2.84 to -0.51The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0128 · Least squares mean difference: -1.64 · 95% CI -2.94 to -0.35The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0037 · Least squares mean difference: -1.91 · 95% CI -3.20 to -0.62The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0048 · Least squares mean difference: -2.11 · 95% CI -3.58 to -0.65The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0020 · Least squares mean difference: -2.30 · 95% CI -3.75 to -0.84The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryLTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-1.51 ± 4.739-2.22 ± 7.305-0.39 ± 3.984-0.39 ± 3.907
Change From Baseline at Week 24-0.54 ± 5.211-2.66 ± 7.2680.11 ± 4.9290.02 ± 5.584
Change From Baseline at Week 52-0.97 ± 5.085-2.81 ± 7.005-0.37 ± 5.775-0.54 ± 5.511
SecondaryLTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-1.93 ± 5.284-2.67 ± 7.160-0.67 ± 4.575-0.66 ± 3.865
Change From Baseline at Week 24-1.22 ± 5.681-3.15 ± 8.2420.02 ± 5.5360.51 ± 5.563
Change From Baseline at Week 52-1.95 ± 4.876-3.31 ± 7.082-0.27 ± 6.506-0.07 ± 5.918
SecondaryVC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)

Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · % BSA
VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)
% BSAVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.43 ± 5.559-3.69 ± 4.230-3.76 ± 4.238
Change From Baseline at Week 4-1.56 ± 4.088-5.29 ± 4.969-5.25 ± 5.190
Change From Baseline at Week 8-2.51 ± 4.722-6.30 ± 5.378-6.54 ± 4.967
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -3.1 · 95% CI -4.07 to -2.18P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -3.7 · 95% CI -4.67 to -2.79P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA

Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · % BSA
LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA
% BSALTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-4.23 ± 4.849-2.84 ± 4.907-6.84 ± 4.852-6.96 ± 4.989
Change From Baseline at Week 16-4.96 ± 5.194-2.98 ± 5.429-7.36 ± 4.875-7.26 ± 5.080
Change From Baseline at Week 20-4.78 ± 5.095-3.75 ± 5.321-7.69 ± 4.901-7.49 ± 5.012
Change From Baseline at Week 24-5.32 ± 4.964-3.85 ± 5.223-7.64 ± 4.998-7.64 ± 4.737
Change From Baseline at Week 28-4.56 ± 5.486-4.43 ± 4.995-7.66 ± 5.029-7.62 ± 4.913
Change From Baseline at Week 32-5.17 ± 4.472-4.53 ± 5.399-7.80 ± 5.011-7.61 ± 5.261
Change From Baseline at Week 36-5.21 ± 4.972-4.39 ± 5.509-8.18 ± 5.111-7.97 ± 5.010
Change From Baseline at Week 40-4.67 ± 5.519-4.75 ± 5.337-8.07 ± 4.899-8.11 ± 4.997
Change From Baseline at Week 44-5.28 ± 5.173-4.56 ± 5.609-8.14 ± 4.789-8.02 ± 4.939
Change From Baseline at Week 48-5.65 ± 5.128-4.58 ± 5.696-8.39 ± 5.023-7.96 ± 4.993
Change From Baseline at Week 52-5.72 ± 5.481-4.93 ± 5.771-8.58 ± 5.013-8.14 ± 4.906
SecondaryVC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score

The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (clear or almost clear) to 28 (very severe eczema). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-2.25 ± 5.779-9.47 ± 7.212-10.60 ± 6.670
Change From Baseline at Week 4-3.38 ± 6.685-10.12 ± 7.380-11.53 ± 6.891
Change From Baseline at Week 8-4.30 ± 7.044-10.60 ± 7.262-11.82 ± 6.931
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -5.1 · 95% CI -6.43 to -3.80P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -6.3 · 95% CI -7.62 to -5.00P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in POEM Score

The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in POEM Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-5.95 ± 6.607-6.89 ± 9.730-10.74 ± 6.653-11.38 ± 6.710
Change From Baseline at Week 24-4.46 ± 6.185-7.26 ± 9.189-10.46 ± 6.655-11.44 ± 6.689
Change From Baseline at Week 52-4.61 ± 6.868-7.00 ± 8.752-10.51 ± 7.396-10.61 ± 7.057
SecondaryVC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score

The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-1.54 ± 4.618-6.18 ± 5.740-6.90 ± 5.980
Change From Baseline at Week 4-2.50 ± 6.101-6.88 ± 5.867-7.15 ± 6.565
Change From Baseline at Week 8-2.83 ± 6.722-7.28 ± 5.907-7.72 ± 6.152
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -3.8 · 95% CI -4.85 to -2.68P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -4.5 · 95% CI -5.56 to -3.42P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in DLQI Score

The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in DLQI Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-3.65 ± 5.602-4.53 ± 6.246-7.67 ± 5.855-7.79 ± 6.240
Change From Baseline at Week 24-3.21 ± 4.814-5.32 ± 6.304-7.87 ± 6.080-7.75 ± 6.277
Change From Baseline at Week 52-3.35 ± 5.438-4.81 ± 6.720-7.95 ± 6.589-7.70 ± 6.443
SecondaryVC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score

CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-1.06 ± 3.733-5.06 ± 6.937-6.76 ± 6.306
Change From Baseline at Week 4-2.47 ± 6.530-4.35 ± 8.683-6.90 ± 5.101
Change From Baseline at Week 8-2.31 ± 5.618-5.88 ± 7.524-7.61 ± 6.142
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0018 · Least squares mean difference: -3.3 · 95% CI -5.29 to -1.26P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0378 · Least squares mean difference: -2.3 · 95% CI -4.43 to -0.13P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in CDLQI Score

CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in CDLQI Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Change From Baseline at Week 12-4.00 ± 5.477-1.13 ± 8.097-5.83 ± 7.661-8.86 ± 5.532
Change From Baseline at Week 24-2.71 ± 5.155-2.00 ± 3.780-6.72 ± 7.640-9.42 ± 7.214
Change From Baseline at Week 52-4.33 ± 8.359-0.43 ± 4.928-6.70 ± 7.766-9.71 ± 6.262
SecondaryVC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 23.53 ± 1.5002.06 ± 0.9371.94 ± 0.911
Week 43.30 ± 1.4341.78 ± 0.9031.68 ± 0.843
Week 83.08 ± 1.4891.76 ± 0.9131.61 ± 0.914
SecondaryVC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 2 - Very Much Improved: 15.331.436.7
Week 2 - Much Improved: 218.638.640.1
Week 2 - Minimally Improved: 337.225.016.9
Week 2 - No Change: 413.34.25.5
Week 2 - Minimally Worse: 511.50.40.8
Week 2 - Much Worse: 610.60.00.0
Week 2 - Very Much Worse: 73.50.40.0
Week 4 - Very Much Improved: 16.748.551.7
Week 4 - Much Improved: 222.929.532.1
Week 4 - Minimally Improved: 338.118.113.3
Week 4 - No Change: 411.43.02.1
Week 4 - Minimally Worse: 511.40.80.8
Week 4 - Much Worse: 66.70.00.0
Week 4 - Very Much Worse: 72.90.00.0
Week 8 - Very Much Improved: 111.048.459.8
Week 8 - Much Improved: 230.033.225.8
Week 8 - Minimally Improved: 329.014.810.0
Week 8 - No Change: 412.01.32.2
Week 8 - Minimally Worse: 57.02.22.2
Week 8 - Much Worse: 610.00.00.0
Week 8 - Very Much Worse: 71.00.00.0
SecondaryVC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 223.9 (16.4 to 32.8)69.9 (63.6 to 75.7)76.8 (70.9 to 82.0)
Week 429.5 (21.0 to 39.2)78.1 (72.2 to 83.2)83.8 (78.5 to 88.2)
Week 841.0 (31.3 to 51.3)81.6 (75.9 to 86.5)85.6 (80.4 to 89.9)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = <0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 6.28 · 95% CI 3.632 to 11.018
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = <0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 8.39 · 95% CI 4.755 to 15.083
SecondaryVC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score

EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.94 ± 14.0466.93 ± 17.6908.21 ± 15.770
Change From Baseline at Week 41.76 ± 11.6188.73 ± 17.4947.10 ± 16.697
Change From Baseline at Week 81.74 ± 14.3769.12 ± 17.8717.98 ± 16.813
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0037 · Least squares mean difference: 4.9 · 95% CI 1.59 to 8.15P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0006 · Least squares mean difference: 5.7 · 95% CI 2.45 to 8.96P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)

The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Work Time Missed Due to AD: Change From Baseline at Week 24.45 ± 19.542-3.89 ± 24.2231.19 ± 14.954
Percent Work Time Missed Due to AD: Change From Baseline at Week 414.09 ± 30.6601.22 ± 23.8983.43 ± 17.242
Percent Work Time Missed Due to AD: Change From Baseline at Week 85.07 ± 23.253-0.26 ± 23.8916.23 ± 22.211
Percent Impairment While Working Due to AD: Change From Baseline at Week 2-7.36 ± 22.630-15.00 ± 22.494-16.75 ± 20.951
Percent Impairment While Working Due to AD: Change From Baseline at Week 4-9.56 ± 25.580-16.86 ± 22.417-19.43 ± 20.933
Percent Impairment While Working Due to AD: Change From Baseline at Week 8-13.54 ± 28.019-19.43 ± 24.878-21.61 ± 22.071
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 2-5.27 ± 21.539-15.04 ± 27.812-15.49 ± 23.785
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 4-2.35 ± 27.602-13.82 ± 26.207-15.82 ± 25.545
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 8-9.01 ± 31.735-18.09 ± 27.718-15.54 ± 27.119
Percent Activity Impairment Due to AD: Change From Baseline at Week 2-6.32 ± 23.434-16.58 ± 24.696-21.56 ± 24.695
Percent Activity Impairment Due to AD: Change From Baseline at Week 4-10.09 ± 26.349-20.80 ± 24.107-23.53 ± 25.422
Percent Activity Impairment Due to AD: Change From Baseline at Week 8-11.70 ± 28.992-21.30 ± 24.653-24.06 ± 26.682
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.1417 · Least squares mean difference: -4.9 · 95% CI -11.49 to 1.65P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.6037 · Least squares mean difference: -1.7 · 95% CI -8.19 to 4.77P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0003 · Least squares mean difference: -11.0 · 95% CI -16.89 to -5.12P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -12.2 · 95% CI -17.98 to -6.47P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -15.4 · 95% CI -22.95 to -7.81P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0011 · Least squares mean difference: -12.4 · 95% CI -19.85 to -5.01P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -10.5 · 95% CI -14.64 to -6.29P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -12.4 · 95% CI -16.60 to -8.29P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in WPAI-SHP v2.0

The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in WPAI-SHP v2.0
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-4.78 ± 18.023-2.02 ± 4.902-0.26 ± 27.1187.72 ± 22.067
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-0.39 ± 21.4664.77 ± 16.899-1.00 ± 28.5114.96 ± 18.942
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-3.92 ± 23.687-3.12 ± 6.143-0.32 ± 27.1158.93 ± 21.916
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-8.11 ± 18.7183.23 ± 26.0081.81 ± 26.0942.38 ± 16.245
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-11.50 ± 23.458-18.64 ± 28.668-20.21 ± 24.925-20.65 ± 21.844
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-8.42 ± 16.754-16.67 ± 28.697-23.51 ± 25.067-23.66 ± 24.396
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-3.13 ± 20.887-8.46 ± 33.378-23.15 ± 25.813-22.72 ± 23.185
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-10.00 ± 25.166-20.00 ± 27.634-23.42 ± 26.597-22.77 ± 24.109
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-12.18 ± 24.763-19.64 ± 28.842-18.21 ± 28.345-14.99 ± 28.777
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-7.46 ± 16.254-12.96 ± 34.336-20.26 ± 31.191-18.60 ± 28.284
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-5.70 ± 23.040-10.43 ± 33.034-20.52 ± 31.307-14.86 ± 29.482
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-16.36 ± 29.721-16.67 ± 40.350-19.42 ± 29.878-20.50 ± 26.949
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-12.20 ± 21.273-8.48 ± 26.244-21.50 ± 26.470-25.19 ± 26.314
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-11.46 ± 16.517-7.14 ± 25.113-22.83 ± 27.440-27.47 ± 25.943
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-6.39 ± 18.997-1.25 ± 27.845-24.48 ± 26.203-26.84 ± 27.493
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-11.05 ± 24.910-13.42 ± 25.392-22.91 ± 27.669-26.92 ± 28.042
SecondaryVC Period: Trough Plasma Concentrations of Ruxolitinib

Plasma samples were collected just before the morning application of study drug during each specified time point.

Time frame:
Pre-dose at Weeks 2, 4 and 8
Reported as:
Mean · nanomole per liter (nM)
VC Period: Trough Plasma Concentrations of Ruxolitinib
nanomole per liter (nM)VC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 226.8 ± 51.233.4 ± 49.9
Week 425.1 ± 42.734.7 ± 43.3
Week 824.0 ± 39.733.3 ± 49.5
SecondaryLTS Period: Trough Plasma Concentrations of Ruxolitinib

Plasma samples were collected just before the morning application of study drug during each specified time point.

Time frame:
Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · nM
LTS Period: Trough Plasma Concentrations of Ruxolitinib
nMLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% CreamLTS Period: Ruxolitinib 1.5% Cream
Week 1213.8 ± 21.321.9 ± 34.416.5 ± 28.124.9 ± 45.4
Week 1611.9 ± 18.818.1 ± 34.619.7 ± 58.824.6 ± 51.0
Week 2013.0 ± 22.215.4 ± 32.016.1 ± 31.224.2 ± 46.1
Week 2413.0 ± 22.118.7 ± 31.618.8 ± 42.424.6 ± 51.8
Week 2818.5 ± 36.915.5 ± 24.616.2 ± 31.223.7 ± 45.3
Week 3217.8 ± 27.317.7 ± 33.321.4 ± 59.821.0 ± 35.3
Week 3621.1 ± 54.829.5 ± 84.015.7 ± 30.526.6 ± 51.2
Week 4014.9 ± 25.316.5 ± 31.014.7 ± 27.623.2 ± 64.1
Week 4414.3 ± 23.715.7 ± 32.617.3 ± 33.526.8 ± 58.6
Week 4815.6 ± 26.817.9 ± 56.015.3 ± 30.324.8 ± 55.3
Week 5211.0 ± 17.914.2 ± 27.511.9 ± 20.521.0 ± 55.7

Adverse events

Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/126 (0%)2/126 (1.6%)10/126 (7.9%)
Ruxolitinib 0.75% Cream BID0/300 (0%)9/300 (3%)52/300 (17.3%)
Ruxolitinib 1.5% Cream BID0/300 (0%)6/300 (2%)70/300 (23.3%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventVehicle Cream BIDRuxolitinib 0.75% Cream BIDRuxolitinib 1.5% Cream BID
Dermatitis atopicSkin and subcutaneous tissue disorders1/1260/3000/300
Nasal sinus cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1260/3000/300
PneumoniaInfections and infestations0/1262/3001/300
Acute abdomenGastrointestinal disorders0/1260/3001/300
ColitisGastrointestinal disorders0/1260/3001/300
Anaemia postoperativeInjury, poisoning and procedural complications0/1261/3000/300
Femur fractureInjury, poisoning and procedural complications0/1261/3000/300
Humerus fractureInjury, poisoning and procedural complications0/1261/3000/300
Pelvic fractureInjury, poisoning and procedural complications0/1261/3000/300
Radius fractureInjury, poisoning and procedural complications0/1261/3000/300
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib 0.75% Cream BIDRuxolitinib 1.5% Cream BID
Upper respiratory tract infectionInfections and infestations4/12627/30036/300
NasopharyngitisInfections and infestations2/12618/30031/300
HeadacheNervous system disorders5/12611/30016/300

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized to the study.

Age, Continuous
Age, Continuous(years)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Mean35.2 ± 18.1136.8 ± 19.0633.7 ± 17.1535.2 ± 18.15
Sex: Female, Male
Sex: Female, Male(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Female79154158391
Male479895240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Hispanic or Latino21303788
Not Hispanic or Latino104218212534
Unknown or Not Reported1449
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
American Indian or Alaska Native0202
Asian8101432
Native Hawaiian or Other Pacific Islander0303
Black or African American295556140
White85173177435
Other49619
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms per square metre (kg/m^2))VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Mean26.92 ± 6.24527.33 ± 6.74527.47 ± 8.07727.30 ± 7.212
08

Study locations

79 sites
  • Cahaba Dermatology
    Birmingham, Alabama 35244, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Specialists Inc
    Oceanside, California 92056, United States
  • Integrated Research Group Inc.
    Riverside, California 92506, United States
  • Advanced Rx Clinical Research
    Westminster, California 92683, United States
  • Clearlyderm Boca Raton - BTC - PPDS
    Boca Raton, Florida 33433, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Acevedo Clinical Research
    Miami, Florida 33142, United States
  • Well Pharma Medical Research Corporation
    Miami, Florida 33143, United States
  • AdvancedPharma CR LLC
    Miami, Florida 33147, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • ForCare Clinical Research
    Tampa, Florida 33624, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Aeroallergy Research Lab Of Savannah
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta - ERN-PPDS
    Stockbridge, Georgia 30281, United States
  • Sneeze Wheeze and Itch Associates LLC
    Normal, Illinois 61761, United States
  • Dawes Fretzin Clinical Research Group LLC
    Indianapolis, Indiana 46256, United States
  • DS Research
    New Albany, Indiana 47150, United States
  • Kansas City Dermatology P.A.
    Overland Park, Kansas 66215, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • Michael W Simon MD
    Nicholasville, Kentucky 40356, United States
  • DermAssociates
    Rockville, Maryland 20850, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • JDR Dermatology Research
    Las Vegas, Nevada 89148, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Sadick Dermatology
    New York, New York 10075, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Ohio Pediatric Research Assn Inc
    Huber Heights, Ohio 45424, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Cyn3rgy Research - Clinedge - PPDS
    Gresham, Oregon 97030, United States
  • Clinical Research Institute Of Southern Oregon - Crisor
    Medford, Oregon 97504, United States
  • Oregon Medical Research Center PC
    Portland, Oregon 97223, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Synexus Clinical Research Us Inc. Greer
    Greer, South Carolina 29651, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
  • Family Medicine Associates Of Texas
    Carrollton, Texas 75010, United States
  • Progressive Clinical Research PA
    San Antonio, Texas 78213, United States
  • Jordan Valley Medical Center
    West Jordan, Utah 84088, United States
  • PI Coor Clinical Research LLC
    Burke, Virginia 22015, United States
  • West End Dermatology
    Henrico, Virginia 23233, United States
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Windsor Clinical Research Inc.
    Windsor, Ontario N8W 5L7, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8X 3V6, Canada
  • Siena Medical Reserch Corporation
    Westmount, Quebec H3Z 2S6, Canada
  • CHRU de Brest - Hopital Morvan
    Brest, 29609, France
  • Le Bateau Blanc - Imm. A
    Martigues, 13500, France
  • Hôpital L'archet 2
    Nice, 06202, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Hôpital Charles Nicolle
    Rouen, 76031, France
  • Elben Klinken Stade - Buxtehude
    Buxtehude, Niedersachsen 21614, Germany
  • Universitätsklinikum Bonn
    Bonn, Nordrhein-Westfalen 53105, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, Sachsen 01307, Germany
  • Universitatsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Synexus (DRS) - Synexus Magyarország Kft. Budapest
    Budapest, 1036, Hungary
  • Synexus Affiliate - Synexus Magyarorszag Kft. Debrecen
    Debrecen, 4025, Hungary
  • Synexus (DRS) - Synexus Magyarország Kft. Gyula
    Gyula, 5700, Hungary
  • Pécsi Tudományegyetem
    Pécs, 7632, Hungary
  • Allergo-Derm Bakos Kft.
    Szolnok, 5000, Hungary
  • Synexus (DRS) - Synexus Magyarország Kft. Zalaegerszeg
    Zalaegerszeg, 8900, Hungary
  • Fondazione Policlinico Universitario A Gemelli
    Roma, 168, Italy
  • Synexus - Wroclaw
    Wroclaw, Dolnoslaskie 50-381, Poland
  • Centrum Medyczne ADAMAR
    Wroclaw, Dolnoslaskie 53-658, Poland
  • ETG Zgierz
    Zgierz, Lódzkie 95-100, Poland
  • Klinika Ambroziak
    Warsaw, Mazowieckie 02-953, Poland
  • Synexus - Gdansk
    Gdansk, Pomorskie 80-382, Poland
  • Laser Clinic S.C.
    Szczecin, Zachodniopomorskie 70-332, Poland
  • Synexus - Katowice
    Katowice, 40-040, Poland
  • Centrum Medyczne Krakow - PRATIA - PPDS
    Krakow, 30-510, Poland
  • ETG Lublin
    Lublin, 20-412, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Poznaniu
    Poznan, 60-702, Poland
  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o
    Tarnow, 33-100, Poland
  • ETG Warszawa
    Warsaw, 02-777, Poland
  • Medycyna Kliniczna Marzena Waszczak-Jeka
    Warszawa, 00-874, Poland
  • Royalderm
    Warszawa, 02-962, Poland
09

References and documents

Publications

  • Bloudek L, Eichenfield LF, Silverberg JI, Joish VN, Lofland JH, Sun K, Augustin M, Migliaccio-Walle K, Sullivan SD. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies. Am J Clin Dermatol. 2023 Jan;24(1):109-117. doi: 10.1007/s40257-022-00734-8. Epub 2022 Oct 20. PubMed 36264430 ↗
  • Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, McGee R, Yeleswaram S. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021 Jul;22(4):555-566. doi: 10.1007/s40257-021-00610-x. Epub 2021 May 12. PubMed 33982267 ↗
  • Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. PubMed 33957195 ↗
  • Scuron MD, Fay BL, Connell AJ, Peel MT, Smith PA. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis. Front Immunol. 2021 Feb 15;11:620098. doi: 10.3389/fimmu.2020.620098. eCollection 2020. PubMed 33658996 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2019, 12 months.

Results were first posted in Dec 2021, 1 year 11 months after primary completion. A results delay was requested in Dec 2020.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Nov 19, 2018
StartActual
Dec 20, 2018
Primary completionActual
Dec 23, 2019
CompletionActual
Dec 1, 2020
Results delay requested
Dec 22, 2020
Results first posted
Dec 17, 2021
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03745638
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Dec 20, 2018
Primary completion
Dec 23, 2019
Completion
Dec 1, 2020
Results posted
Dec 17, 2021
Last update
Sep 28, 2023

Study contacts

Michael E. Kuligowski, MD, PhD, MBA
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion